Adverse events666

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 666

Type	Event	Organ system	Group	Affected	At risk
other	Acquired antithrombin III deficiency	Blood and lymphatic system disorders	Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy	0	45
other	Acquired antithrombin III deficiency	Blood and lymphatic system disorders	Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy	0	32
other	Acquired antithrombin III deficiency	Blood and lymphatic system disorders	Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2	1	14
other	Acquired antithrombin III deficiency	Blood and lymphatic system disorders	Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma	0	4
other	Acquired antithrombin III deficiency	Blood and lymphatic system disorders	Cohort 5: Primary Central Nervous System Lymphoma	0	7
other	Acquired antithrombin III deficiency	Blood and lymphatic system disorders	Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting	0	11
other	Anaemia	Blood and lymphatic system disorders	Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy	21	45
other	Anaemia	Blood and lymphatic system disorders	Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy	8	32
other	Anaemia	Blood and lymphatic system disorders	Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2	10	14
other	Anaemia	Blood and lymphatic system disorders	Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma	0	4
other	Anaemia	Blood and lymphatic system disorders	Cohort 5: Primary Central Nervous System Lymphoma	3	7
other	Anaemia	Blood and lymphatic system disorders	Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting	2	11
other	Eosinophilia	Blood and lymphatic system disorders	Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy	0	45
other	Eosinophilia	Blood and lymphatic system disorders	Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy	0	32
other	Eosinophilia	Blood and lymphatic system disorders	Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2	1	14
other	Eosinophilia	Blood and lymphatic system disorders	Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma	0	4
other	Eosinophilia	Blood and lymphatic system disorders	Cohort 5: Primary Central Nervous System Lymphoma	0	7
other	Eosinophilia	Blood and lymphatic system disorders	Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting	0	11
other	Febrile neutropenia	Blood and lymphatic system disorders	Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy	5	45
other	Febrile neutropenia	Blood and lymphatic system disorders	Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy	1	32

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03484702/events

API reference For AI assistants

Adverse events666

Sources 3

Read this list from software.